| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net (loss) income | -3,962 | -915 | 21,490 | -8,475 |
| Net (loss) income attributable to series c preferred stockholders, basic | - | -290 | 6,407 | - |
| Net (loss) income attributable to common stockholders, basic | -3,035 | -625 | 15,083 | - |
| Earnings per share, basic | -0.34 | -0.11 | 2.17 | -8.81 |
| Earnings per share, diluted | -0.34 | -0.11 | 2.09 | -8.81 |
| Weighted average number of shares outstanding, basic | 8,818,859 | 5,820,903 | 6,965,927 | 961,530 |
| Weighted average number of shares outstanding, diluted | 8,818,859 | 5,820,903 | 7,215,125 | 961,530 |
Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc. (TRAW)